TOP TEN perturbations for 38752_r_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38752_r_at
Selected probe(set): 209492_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38752_r_at (209492_x_at) across 6674 perturbations tested by GENEVESTIGATOR:

kidney transplantation study 16 (2 week) / normal natural killer cell (CD56+) sample

Relative Expression (log2-ratio):-2.5851736
Number of Samples:3 / 3
Experimental kidney transplantation study 16 (2 week)
CD56+ natural killer cell samples derived from kidney transplant patients 2 weeks post-transplantation. Samples were collected 2 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal natural killer cell (CD56+) sample
CD56+ natural killer cell samples derived from healthy control subjects.

ovarian tumor study 11 (low grade) / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):2.3979673
Number of Samples:11 / 6
Experimental ovarian tumor study 11 (low grade)
Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma.
Control normal ovarian surface epithelial cell sample
Human microdissected ovarian surface epithelial cell sample from the ovary of healthy individuals.

sirolimus study 6 (light) / sirolimus study 6 (heavy)

Relative Expression (log2-ratio):2.0687284
Number of Samples:3 / 3
Experimental sirolimus study 6 (light)
Human fetal lung fibroblast cell line (MRC5) treated for 50 minutes with sirolimus (100 nM; vendor: LC laboratories / catalog name: rapamycin). Cells in the growing phase (at 60% confluency) were hypertonically shocked by changing the condition media to a 300 mM NaCl containing Medium for 30 minutes. After hypertonic shock cells were transferred back to isotonic conditions for additional 30 min. Rapamycin was added to the cells during hypertonic shock until the end of recovery (50 minutes total exposure). After treatment RNA was isolated from the light polysome fraction. ATC code:
Control sirolimus study 6 (heavy)
Human fetal lung fibroblast cell line (MRC5) treated for 50 minutes with sirolimus (100 nM; vendor: LC laboratories / catalog name: rapamycin). Cells in the growing phase (at 60% confluency) were hypertonically shocked by changing the condition media to a 300 mM NaCl containing Medium for 30 minutes. After hypertonic shock cells were transferred back to isotonic conditions for additional 30 min. Rapamycin was added to the cells during hypertonic shock until the end of recovery (50 minutes total exposure). After treatment RNA was isolated from the heavy polysome fraction. ATC code:

interferon-alpha-kinoid study 2 (240ug; 168d) / placebo treated whole blood sample

Relative Expression (log2-ratio):-2.0098276
Number of Samples:3 / 6
Experimental interferon-alpha-kinoid study 2 (240ug; 168d)
Whole blood samples of patients with systemic lupus erythematosus after treatment with interferon-alpha-kinoid (INF-K; inactivated IFNa coupled keyhole limpet hemocyanin as carrier). Patients had 4 doses of 240ug INK-K at day 0, 7, 58 and 84. Sample was taken 168 days after the first application of TNF-K. ATC code:---
Control placebo treated whole blood sample
Whole blood samples of patients with systemic lupus erythematosus after treatment with placebo (0.9% NaCl; hemocyanin as carrier). Patients had 3 doses at day 0, 7 and 58. Sample was taken 168 days after the first application of TNF-K.

interferon-alpha-kinoid study 2 (120ug; 168d) / untreated whole blood sample

Relative Expression (log2-ratio):1.9288464
Number of Samples:2 / 43
Experimental interferon-alpha-kinoid study 2 (120ug; 168d)
Whole blood samples of patients with systemic lupus erythematosus after treatment with interferon-alpha-kinoid (INF-K; inactivated IFNa coupled keyhole limpet hemocyanin as carrier). Patients had 4 doses of 120ug INK-K at day 0, 7, 58 and 84. Sample was taken 168 days after the first application of TNF-K. ATC code:---
Control untreated whole blood sample
Whole blood samples from healthy volunteers.

interferon-alpha-kinoid study 1 (120ug; 112d) / untreated whole blood sample

Relative Expression (log2-ratio):1.9077053
Number of Samples:3 / 43
Experimental interferon-alpha-kinoid study 1 (120ug; 112d)
Whole blood samples of patients with systemic lupus erythematosus after treatment with interferon-alpha-kinoid (INF-K; inactivated IFNa coupled keyhole limpet hemocyanin as carrier). Patients had 3 doses of 120ug INK-K at day 0, 7 and 58. Sample was taken 112 days after the first application of TNF-K. ATC code:---
Control untreated whole blood sample
Whole blood samples from healthy volunteers.

interferon-alpha-kinoid study 1 (30ug; 112d) / untreated whole blood sample

Relative Expression (log2-ratio):1.9024792
Number of Samples:3 / 43
Experimental interferon-alpha-kinoid study 1 (30ug; 112d)
Whole blood samples of patients with systemic lupus erythematosus after treatment with interferon-alpha-kinoid (INF-K; inactivated IFNa coupled keyhole limpet hemocyanin as carrier). Patients had 3 doses of 30ug INK-K at day 0, 7 and 58. Sample was taken 112 days after the first application of TNF-K. ATC code:---
Control untreated whole blood sample
Whole blood samples from healthy volunteers.

ovarian tumor study 11 (borderline) / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):1.7802992
Number of Samples:8 / 6
Experimental ovarian tumor study 11 (borderline)
Human microdissected tumor cells from the ovary of patients with low-malignant (borderline) tumors of the ovary.
Control normal ovarian surface epithelial cell sample
Human microdissected ovarian surface epithelial cell sample from the ovary of healthy individuals.

interferon-alpha-kinoid study 2 (60ug; 168d) / untreated whole blood sample

Relative Expression (log2-ratio):1.7625332
Number of Samples:3 / 43
Experimental interferon-alpha-kinoid study 2 (60ug; 168d)
Whole blood samples of patients with systemic lupus erythematosus after treatment with interferon-alpha-kinoid (INF-K; inactivated IFNa coupled keyhole limpet hemocyanin as carrier). Patients had 4 doses of 60ug INK-K at day 0, 7, 58 and 84. Sample was taken 168 days after the first application of TNF-K. ATC code:---
Control untreated whole blood sample
Whole blood samples from healthy volunteers.

interferon-alpha-kinoid study 1 (120ug; 168d) / untreated whole blood sample

Relative Expression (log2-ratio):1.7384138
Number of Samples:3 / 43
Experimental interferon-alpha-kinoid study 1 (120ug; 168d)
Whole blood samples of patients with systemic lupus erythematosus after treatment with interferon-alpha-kinoid (INF-K; inactivated IFNa coupled keyhole limpet hemocyanin as carrier). Patients had 3 doses of 120ug INK-K at day 0, 7 and 58. Sample was taken 168 days after the first application of TNF-K. ATC code:---
Control untreated whole blood sample
Whole blood samples from healthy volunteers.